title: Minimum MD simulation length required to achieve reliable results in free energy perturbation calculations: case study of relative binding free energies of fructose-1,6-bisphosphatase inhibitors.
abstract: In an attempt to establish the criteria for the length of simulation to achieve the desired convergence of free energy calculations, two studies were carried out on chosen complexes of FBPase-AMP mimics. Calculations were performed for varied length of simulations and for different starting configurations using both conventional- and QM/MM-FEP methods. The results demonstrate that for small perturbations, 1248 ps simulation time could be regarded a reasonable yardstick to achieve convergence of the results. As the simulation time is extended, the errors associated with free energy calculations also gradually tapers off. Moreover, when starting the simulation from different initial configurations of the systems, the results are not changed significantly, when performed for 1248 ps. This study carried on FBPase-AMP mimics corroborates well with our previous successful demonstration of requirement of simulation time for solvation studies, both by conventional and ab initio FEP. The establishment of aforementioned criteria of simulation length serves a useful benchmark in drug design efforts using FEP methodologies, to draw a meaningful and unequivocal conclusion.
authors.affiliation: Bioinformatics Infrastructure Facility, Department of Biotechnology, School of Life Sciences, University of Hyderabad, Hyderabad 500 046, India.
authors.forename: R S
authors.initials: RS
authors.lastname: Rathore
authors.forename: P
authors.initials: P
authors.lastname: Aparoy
authors.forename: P
authors.initials: P
authors.lastname: Reddanna
authors.forename: A K
authors.initials: AK
authors.lastname: Kondapi
authors.forename: M Rami
authors.initials: MR
authors.lastname: Reddy
mesh_terms: D000249:Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D003920:Diabetes Mellitus / Q000201:enzymology*; D015195:Drug Design; D006597:Fructose-Bisphosphatase / Q000037:antagonists & inhibitors*; D056004:Molecular Dynamics Simulation; D013816:Thermodynamics
chemical_list: D000249:Adenosine Monophosphate; D006597:Fructose-Bisphosphatase